SEC Form 4 · accession 0001562180-16-002434
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theodore Alan Huizenga
Officer — Controller and PAO
Period of report
May 25, 2016
Accepted (ET)
May 27, 2016 · 4:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 25, 2016 | A | 5,000 | $0.00 | A | 9,334 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $68.59 | May 25, 2016 | A | 10,000 | A | — | May 25, 2026 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1Award of Restricted Stock Units under the Company's 2014 Incentive Plan that vests with respect to 1/4 of the underlying shares on each anniversary of the grant date such that the Restricted Stock Units are fully vested on the fourth anniversary of the grant date.
- F2Includes shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
- F3The options shall vest with respect to 1/4th of the underlying shares on the first anniversary of the grant date and then with respect to 1/48th of the underlying shares monthly thereafter.